R207910 (TMC207): A new antibiotic for the treatment of tuberculosis;R207910 (TMC207) : Un nouvel antibiotique pour le traitement de la tuberculose

Medecine et Maladies Infectieuses

Volumn 40, Issue 7, 2010, Pages 383-390

  Lounis, N ^a   Guillemont, J ^b   Veziris, N ^c,d,e   Koul, A ^a   Jarlier, V ^c,d,e   Andries, K ^a  

^a JOHNSON AND JOHNSON   (United States)

^b Janssen Cilag Research Center   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (France)

Author keywords

Diarylquinolines; R207910; TMC207; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; AMIKACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MOXIFLOXACIN; NITRIC OXIDE; PLACEBO; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM CULTURE; DISEASE MODEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HYPOXIA; IN VITRO STUDY; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; SEROCONVERSION; SPUTUM CULTURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUBERCULOSIS;

EID: 77955049890     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2009.09.007     Document Type: Review

References (23)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva: WHO; 2007.
2. Gaurrand S., Desjardins S., Meyer C., Bonnet P., Argoullon J.M., Oulyadi H., et al. Conformational analysis of R207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. Chemical Biology & Drug Design 2006, 68:77-84.
3. Petit S., Coquerel G., Meyer C., Guillemont J. Absolute configuration and structural features of R207910, a novel anti-tuberculosis agent. Journal of Molecular Structure 2007, 837:252-256.
4. Andries K., Verhasselt P., Guillemont J., Göhlmann H.W.H., Neefs J.M., Winkler H., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
5. Koul A., Dendouga N., Vergauwen K., Molenberghs B., Vranckx L., Willebrords R., et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chemical Biology 2007, 3:323-324.
6. Huitric E., Verhasselt P., Andries K., Hoffner S.E. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrobial Agents and Chemotherapy 2007, 51:4202-4204.
7. Reddy V.M., Einck L., Andries K., Nacy C.A. The new antitubercular drugs SQ109 and TMC207 act synergistically in vitro to kill M. tuberculosis. 48th Annual ICAAC/IDSA 46th Annual Meeting 2008, [Abstract No. C1-3848].
8. Koul A., Vranckx L., Dendouga N., Balemans W., Van den Wyngaert I., Vergauwen K., et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. Journal of Biological Chemistry 2008, 37:25273-25280.
9. Lounis N., Gevers T., Van Den Berg J., Verhaeghe T., van Heeswijk R., Andries K. Prevention of drug carryover effects in studies assessing the antimycobacterial efficacy of TMC207. Journal of Clinical Microbiology 2008, 46:2212-2215.
10. Diacon A.H., Pym A., Grobusch M., Patientia M., Rustomjee R., Page-Shipp L., et al. The investigational diarylquinoline TMC207 for multidrug-resistant TB. New England Journal of Medicine 2009, 360:2397-2405.
11. Haagsma A.C., Ibrahim R.A., Wagner M.J., Krab K., Vergauwen K., Guillemont J., et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrobial Agents and Chemotherapy 2009, 53:1290-1292.
12. Veziris N., Ibrahim M., Truffot-Pernot C., Andries K., Jarlier V. R207910 containing regimens display high sterilizing activity in the murine model of tuberculosis. 47 Interscience Conference on Antimicrobial Agents and Chemotherapy 2007, [Abstract No. B-1225].
13. Nuermberger E., Yoshimatsu T., Tyagi S., Williams K., Rosenthal I., O'Brien R., et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine 2004, 170:1131-1134.
14. Dorman S.E., Johnson J.L., Goldberg S., Muzanye G., Padayatchi N., Bozeman L., et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 2009, 180:273-280.
15. Lounis N., Gevers T., Van Den Berg J., Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrobial Agents and Chemotherapy 2008, 52:3568-3572.
16. Veziris N., Ibrahim M., Lounis N., Chauffour A., Truffot-Pernot C., Andries K., et al. A once weekly R207910 containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine 2009, 179:75-79.
17. Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrobial Agents and Chemotherapy 2006, 50:3543-3547.
18. Veziris N., Truffot-Pernot C., Aubry-Damon A., Jarlier V., Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrobial Agents and Chemotherapy 2003, 47:3117-3122.
19. Ibrahim M., Truffot-Pernot C., Andries K., Jarlier V., Veziris N. Sterilizing activity of a second line regimen including R207910 (TMC207) in murine tuberculosis. 48th Annual ICAAC/IDSA 46th Annual Meeting 2008, [Abstract No. B-876].
20. Lenaerts A.J., Hoff D., Aly S., Ehlers S., Andries K., Cantarero L., et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrobial Agents and Chemotherapy 2007, 51:3338-3345.
21. Rustomjee R., Diacon A.H., Allen J., Venter A., Reddy C., Patienta R.F., et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 2008, 52:2831-2835.
22. Ginsberg A., Diacon A., Dawson R., Whitney K., Rouse D., Laurenzi M., et al. Extended early bactericidal activity (EBA) of PA-824, a novel drug for tuberculosis treatment. 48th Annual ICAAC/IDSA 46th Annual Meeting 2008, [Abstract No. B-881a].
23. Ginsberg A., Diacon A.M. Development of new drugs for tuberculosis. Infectious Diseases Society of America (IDSA) 45th Annual Meeting 2007.